Charting a New Course in Immunology and Oncology Drug Development
Immune-Onc is a clinical-stage biopharmaceutical company advancing novel therapies that target myeloid cells
We believe myeloid cell surface proteins represent the next wave of therapeutic targets in immunology and oncology. In collaboration with scientists, our research team is among the first in the world to validate these cell surface molecules as targets for novel therapies that have the potential to transform current treatment approaches for blood cancers, solid tumors as well as autoimmune and inflammatory diseases.
Turning the Tide on Immune Regulation
Immunotherapy, which harnesses the body’s own immune system to fight against disease, has changed the way we think about treatment — and even cures. Recent breakthroughs in our understanding of the role of myeloid cells may yield entirely novel therapies that can further unlock the immune system’s ability to defeat certain cancers and autoimmune diseases.
Translating Scientific Discoveries Into Breakthrough Treatments
In recent years, T-cell checkpoint inhibitors such as anti-PD-(L)1 have emerged as the standard-of-care for the treatment of multiple solid tumor cancers. While this progress is encouraging, to date, these therapies have only been effective in a subset of patients. Currently, 70-80 percent of cancer patients with solid tumors do not achieve durable responses to T-cell checkpoint therapies, and people with many types of blood cancers, including acute myeloid leukemia (AML), have yet to benefit from the promise of immunotherapy.
At Immune-Onc, we aspire to help more people benefit from immunotherapy. We are building a portfolio of novel antibodies that modulate or deplete specific subsets of myeloid cells involved in disease pathogenesis. We believe they will form the next wave of groundbreaking therapies for blood cancers, solid tumors and autoimmune diseases.
Collaborators & Investors
The team at Immune-Onc Therapeutics has significant industry experience in bringing innovative biologic treatments to patients with serious diseases. Combining our deep expertise in drug development with strategic research collaborations with leading academic institutions and nonprofit patient organizations, we aim to discover and develop new immunomodulatory agents for treatment of autoimmune diseases and cancers. Our efforts are backed by seasoned investors committed to making our vision a reality for patients.